ReviewHistopathology2025
Pathology reporting of hepatoblastoma resections: recommendations from the international collaboration on cancer reporting.
Review in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHepatoblastoma is the most common primary malignant tumour of the liver diagnosed in children and its incidence is increasing worldwide. Ongoing international clinical trials and scientific collaborative efforts are attempting to standardize the diagnosis, risk stratification and management of young patients diagnosed with this rare cancer, which includes surgical resection of the tumour. Here we report the international consensus-based dataset for the pathology reporting of hepatoblastoma resection specimens. The dataset was developed under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of international pathology and cancer organizations. METHODS AND
resultsAccording to the ICCR's guidelines for dataset development, an international expert panel including paediatric pathologists and a paediatric oncologist specialized in liver tumours developed a set of core and non-core data items for hepatoblastoma resection specimens based on critical review and discussion of current evidence available. Members of the panel were specialists working in tertiary paediatric hospitals, central reviewers for international paediatric liver tumours consortia and/or involved in paediatric liver tumour trials expert committees. Commentaries were provided to support each data item, explaining the rationale for selecting them as a 'core' or 'non-core' elements, their clinical relevance and highlighting potential areas of lack of evidence, including clinical, macroscopic, microscopic and ancillary testing considerations. The hepatoblastoma dataset was finalized and ratified following international public consultation and is published on the ICCR website for wide implementation.
conclusionThis is the first international dataset developed by an international expert panel for reporting hepatoblastoma resection specimens aimed to promote high-quality, standardized pathology reporting of these rare paediatric liver tumours. The adoption and implementation of this hepatoblastoma data set, freely available worldwide on the ICCR website (www.iccr-cancer.org/data-sets), will facilitate accurate reporting and enhance the consistency of data collection, support retrospective and inform prospective research and ultimately help to improve clinical outcomes of children with hepatoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.